It provides superior phototherapy performance, individualized therapy with electronic documentation capabilities and the flexibility for seamless integration into practically every workplace.

Optimizing use of topical agents begins with defining "mild or moderate." Clinical trials in psoriasis employ objective ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality ...

Otulfi, an ustekinumab biosimilar for the reference product Stelara (ustekinumab), developed by Formycon AG, is now available ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Dialectical behavior therapy (DBT) is an evidence-based talk therapy that originated from cognitive behavioral therapy (CBT) but more directly focuses on the needs of those prone to suicide or ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...

BRIDGEWATER, NJ, USA and BENGALURU, India I March 7, 2025 I Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and ...

Selarsdi (ustekinumab-aekn; Teva and Alvotech), and Yesintek (ustekinumab-kfce; Biocon Biologics), all biosimilars to Stelara (ustekinumab; Johnson & Johnson) are now available in the US.